162 related articles for article (PubMed ID: 18555493)
1. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells.
Horiguchi A; Asano T; Asano T; Ito K; Sumitomo M; Hayakawa M
J Urol; 2008 Aug; 180(2):729-36. PubMed ID: 18555493
[TBL] [Abstract][Full Text] [Related]
2. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
3. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
4. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.
Alli PM; Pinn ML; Jaffee EM; McFadden JM; Kuhajda FP
Oncogene; 2005 Jan; 24(1):39-46. PubMed ID: 15489885
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of an imidazoquinoline in renal cell carcinoma.
Schwartz MJ; Liu H; Hwang DH; Kawamoto H; Scherr DS
Urology; 2009 May; 73(5):1156-62. PubMed ID: 19118885
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.
Zhou W; Simpson PJ; McFadden JM; Townsend CA; Medghalchi SM; Vadlamudi A; Pinn ML; Ronnett GV; Kuhajda FP
Cancer Res; 2003 Nov; 63(21):7330-7. PubMed ID: 14612531
[TBL] [Abstract][Full Text] [Related]
8. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts.
Pizer ES; Thupari J; Han WF; Pinn ML; Chrest FJ; Frehywot GL; Townsend CA; Kuhajda FP
Cancer Res; 2000 Jan; 60(2):213-8. PubMed ID: 10667561
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.
Puig T; Vázquez-Martín A; Relat J; Pétriz J; Menéndez JA; Porta R; Casals G; Marrero PF; Haro D; Brunet J; Colomer R
Breast Cancer Res Treat; 2008 Jun; 109(3):471-9. PubMed ID: 17902053
[TBL] [Abstract][Full Text] [Related]
11. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
Pizer ES; Pflug BR; Bova GS; Han WF; Udan MS; Nelson JB
Prostate; 2001 May; 47(2):102-10. PubMed ID: 11340632
[TBL] [Abstract][Full Text] [Related]
12. Increased fatty acid synthase is a therapeutic target in mesothelioma.
Gabrielson EW; Pinn ML; Testa JR; Kuhajda FP
Clin Cancer Res; 2001 Jan; 7(1):153-7. PubMed ID: 11205903
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma.
Horiguchi A; Asano T; Asano T; Ito K; Sumitomo M; Hayakawa M
J Urol; 2008 Sep; 180(3):1137-40. PubMed ID: 18639282
[TBL] [Abstract][Full Text] [Related]
14. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
15. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Kanao K; Mikami S; Mizuno R; Shinojima T; Murai M; Oya M
J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of fatty acid synthase for lung cancer treatment.
Orita H; Coulter J; Lemmon C; Tully E; Vadlamudi A; Medghalchi SM; Kuhajda FP; Gabrielson E
Clin Cancer Res; 2007 Dec; 13(23):7139-45. PubMed ID: 18056164
[TBL] [Abstract][Full Text] [Related]
17. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
18. A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells.
Fujimoto E; Sato H; Nagashima Y; Negishi E; Shirai S; Fukumoto K; Hagiwara H; Hagiwara K; Ueno K; Yano T
Life Sci; 2005 Apr; 76(23):2711-20. PubMed ID: 15792837
[TBL] [Abstract][Full Text] [Related]
19. The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro.
Arai Y; Nonomura N; Nakai Y; Nishimura K; Oka D; Shiba M; Nakayama M; Takayama H; Mizutani Y; Miki T; Okuyama A
Cancer Invest; 2008 Feb; 26(1):35-40. PubMed ID: 18181043
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines.
Pizer ES; Chrest FJ; DiGiuseppe JA; Han WF
Cancer Res; 1998 Oct; 58(20):4611-5. PubMed ID: 9788612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
